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ABSTRACT 
Platelet-derived growth factor (PDGFB) is a critical molecule for recruiting pericytes. Due to 
the fundamental role of the pericytes in angiogenesis and vascular stability, PDGFB knockout 
mice die perinatally from severe hemorrhage and edema. PDGFB retention motif knockout 
mouse (Pdgfb
ret/ret
) is one of the available models to study the postnatal effect of PDGFB 
signaling. My PhD projects intensively used Pdgfb
ret/ret
 to explore the role of PDGFB in 
cholesterol and glucose metabolism. 
In the brain, the pericyte coverage on the blood-brain barrier (BBB) of Pdgfb
ret/ret
 is reduced 
by 70%, which leads to increased permeability to a series of high- and low-mass tracers. 
Physiologically cholesterol metabolism in the brain is isolated from the other organs or the 
circulation by BBB. Paper I and II used Pdgfb
ret/ret
 mice as a BBB leakage model and studied 
the metabolic changes of cholesterol metabolism in the brain when BBB lose its integrity. 
Our results show that in Pdgfb
ret/ret
, more plant sterols are accumulated in the brain due to 
increased influx. Meanwhile due to increased efflux of 24(S)-hydroxycholesterol, the 
negative feedbacks to de novo biosynthesis of cholesterol in the brain is diminished.  
Liver has been considered as a special organ for PDGFB signaling, because recruitment of 
the hepatic stellate cells (HSCs), also disputably known as the liver pericytes, are recruited 
independently of PDGFB. PDGFB is known to be expressed from the endothelial cells of 
portal veins, but its physiological role is still poorly investigated. In Paper III, we describe 
for the first time that cholangiocytes, the epithelial cells of bile ducts, are also expressing 
PDGFB. Similar to pericyte deficiency on BBB, Pdgfb
ret/ret
 mice show deficiency of 
periductal mesenchymal cells, together with bile duct dilation and portal inflammatory 
infiltrate (PII). PII is of great clinical importance, because it is an early marker ubiquitously 
present in many biliary and non-biliary liver diseases. Using Pdgfb
ret/ret
, together with PDGFB 
knockouts and Sox2-Cre;PDGFRβ+/D849V mutants in which PDGFRβ is over-active, we 
confirmed that elevated PDGFB signaling leads to PII directly. In Pdgfb
ret/ret
, PII is 
accompanied by a lopsided immune profile, with increased CD8 T cells and decreased NKT 
cells, which mimics the immune profile at the steatosis stage of non-alchoholic fatty liver 
diseases. From metabolic perspective, we show that immune response in Pdgfb
ret/ret
 leads 
further to intolerance to high cholesterol diet and susceptibility to hepatic steatosis by 
suppressing VLDL secretion.  
Paper IV focuses on the function of PDGFB in pancreatic islets. We show that PDGFB is 
not a key factor to maintain the pericyte coverage in pancreatic islets. In Pdgfb
ret/ret
, the 
slightly disrupted PDGFB signaling is not enough to affect vascular functions in pancreatic 
islets. The first phase of insulin secretion in Pdgfb
ret/ret
 is earlier and stronger, and our current 
data indicates a systematic factor as the underlying mechanism.  
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1 INTRODUCTION 
1.1 CHOLESTEROL PHYSIOLOGY 
Cholesterol (C27H46O) is a lipid molecule essential for cell membranes of all animals. In 
adult humans, the average turnover of cholesterol is estimated to be 1.2g per day. 
Structurally, cholesterol has a steroid ring structure at the centre with a polar hydroxyl 
group on one side and a nonpolar hydrocarbon tail on the other side. When forming cell 
membranes, the hydrocarbon tail is sitting in the hydrophobic plane with the hydroxyl head 
facing either out or into the cell. The hydroxyl group interacts with polar head groups of 
different phospholipids and sphingolipids, thus forming the lipid bilayer. Cholesterol is of 
great importance for the structural integrity of the cell membrane. The cholesterol content 
and distribution in cell membranes varies in different cell types, and cholesterol can 
modulate these membranes’ physical characteristics. Cholesterol-rich regions have higher 
fluidity because cholesterol molecules are inserted between acyl chains, thus preventing 
them from crystallization and limiting their movements. Meanwhile, cholesterol increases 
the bilayer’s thickness, thus decreasing the permeability to soluble ions and small 
molecules
1
.  
However, cholesterol is not only a structural component of cell membranes, but also plays an 
important role in cell signalling. Caveolin is a cholesterol-binding protein highly concentrated 
on a small dynamic lipid patch on cell plasma membranes called caveolae. Studies have 
shown that many membrane receptors are located on caveolae or caveolae-like domains, 
where caveolin functions as a bridge between the receptor and its effector to transduce 
signals
1
. Besides, caveolae itself is a cholesterol-rich region, and it has been shown that 
cholesterol amount also affect the receptors’ stability by modulating the physical 
characteristics of caveolae
2
. Meanwhile cholesterol is the precursor of many steroid 
hormones in the body such as glucocorticoids, sex hormones and vitamin D. Steroid 
hormones are lipid-soluble, so they can easily diffuse via cell membrane and bind to their 
receptors in the cytoplasm. Then the activated receptor can be translocated into the nucleus 
and cast its effect by binding to genomic DNA and regulating its transcription. Through this 
ligand-receptor mechanism, steroid hormones are involved in different biological process, 
such as metabolism, immune response and development of sexual characteristics
3
. 
1.1.1 Cholesterol homeostasis in liver 
Liver is the key organ to maintain cholesterol homeostasis outside the brain. Through blood 
circulation, the liver distributes necessary cholesterol to the peripheral tissues and recycles the 
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surplus. Through enterohepatic circulation, the liver intakes cholesterol from dietary and 
excrete excessive cholesterol into the intestine in the form of bile. Meanwhile, the liver 
compensates 20-50% of all cholesterol in mammals through de novo biosynthesis and this 
process is precisely regulated by the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-
coenzym A (HMG-CoA) reductase
4
. In this thesis, the de novo biosynthesis will not be 
further introduced, since we did not detect major changes in this process when exploring the 
role of PDGFB signalling in liver.  
1.1.1.1 Liver anatomy 
From metabolic perspective, the basic functional unit in the liver is the hepatic acinus, which 
is formed by two portal triads, two central veins and the tissue in-between. A portal triad 
consists of a hepatic artery, which supplies the liver with oxygenated blood, a hepatic portal 
vein, which brings nutrient-rich blood directly from the intestine, and a bile duct, which 
excretes excessive cholesterol and bile products out of the body. Blood converged from both 
the hepatic portal vein and the hepatic artery drains into the central vein through a highly-
permeable capillary called sinusoid. As shown in Figure 1, sinusoid is composed of 
endothelial cells and aligns closely with the bile ducts. Lining the sinusoid there are kupffer 
cells, the specialized macrophages and hepatic stellate cells (HSCs), the liver pericytes which 
are critically involved in the pathogenesis of hepatic fibrosis. Around sinusoids, 70-85% of 
the liver mass is filled with hepatocytes, the major cell type of hepatic parenchymal tissues, 
which are responsible for the entire protein, carbohydrate and lipid metabolism in the liver. 
 
Figure1. Structure of hepatic sinusoid
5
 
1.1.1.2 Cholesterol distribution through blood circulation 
The transportation of cholesterol in the water-soluble blood circulation requires lipoproteins, 
because cholesterol and its stored form, cholesterol ester, are hydrophobic. Lipoproteins are 
macromolecular lipid-protein complexes with a hydrophobic core inside and a relatively 
hydrophilic coating outside (Fig2). The hydrophobic core contains triacylglycerol and 
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cholesterol esters, and the coating is a monolayer of phospholipids and cholesterol. 
Cholesterol and phospholipids make lipoproteins stable and soluble in water by aligning their 
hydrophilic heads outwards. 
 
Figure2 Structure of lipoproteins
6 
Lipoproteins are labelled with different apolipoproteins. These apolipoproteins functions as 
fingerprints; therefore peripheral organs can recognize different lipoproteins and make use of 
the lipids inside. Based on density, size, apolipoprotein and composition, lipoproteins are 
classified into different groups or fractions: chylomicron, very low-density lipoprotein 
(VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL)
7
. The main 
characteristics of these lipoprotein fractions are shown in Table 1.  
 
Table1. Main characteristics of lipoprotein fractions
7
 
VLDL has Apolipoprotein B100 (ApoB100) as the structural apolipoprotein and loads 
cholesterol, together with triacylglycerol (TG), with the facilitation of microsomal 
triglyceride transfer protein (MTTP). Through VLDL, cholesterol and TG is supplied from 
the liver to the peripheral tissues. Because the peripheral tissues extract the TG much faster 
than the cholesterol, VLDLs increase in density and transform into LDLs. LDLs then travel 
back to the liver and are recognized by LDL receptors. Pathologically, elevated levels of 
VLDL and LDL are the pre-requisite factor for developing atherosclerosis
8
. Atherosclerosis is 
a chronic inflammatory disease, which accounts for 50% of all deaths in westernized 
countries. The atherosclerotic process initiates from the accumulation of cholesterol-
containing lipoproteins in the intima and decades later underlines the cause of most 
cardiovascular diseases, including myocardial infarction, stroke and ischemic gangrene
9
. 
HDLs, on the other hand, remove cholesterol and TG from the peripheral tissues and 
transport them back to the liver for excretion. HDL has Apolipoprotain A1 (ApoA1) as the 
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structural protein and loads cholesterol under the help of ATP-binding cassette transporter 
(ABCA1)
7
. 
1.1.1.3 Bile synthesis and enterohepatic circulation 
 
Figure 3 Bile acid syntheses
10
  
The excessive cholesterol in the liver is converted into bile acids and later bile salts for 
excretion. Bile acids are synthesized in hepatocytes mainly by two pathways: neutral and 
alternative. As is shown in figure 3, cholesterol 7 alpha-hydroxylase (CYP7A1) is considered 
as the rate-limiting enzyme along the neutral pathway. This enzyme is regulated by a feed-
back suppressive mechanism at the transcription level. When the end products of the neutral 
pathway, mainly cholic acid and chenodeoxycholic acid, are retentioned in the intestine, they 
stimulate the secretion of fibroblast growth factor 15/19 (FGF15/19). FGF15/19 is a hormone 
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which circulates back to the liver, signaling the hepatocytes by binding to its receptors and 
downregulating the gene expression of CYP7A. Several studies have shown that this down-
regulation involves both c-Jun N-terminal kinase (JNKs) and extracellular signal-regulated 
kinases (ERK) signaling cascades
11
. The alternative pathway, also called the acidic pathway, 
is initiated by the enzyme sterol 27-hydroxylase (CYP27A1). Bile acid synthesis along the 
acidic pathway happens in mitochondria and the specific transporter Steroidogenic acute 
regulatory (StARD1) is required to help cholesterol pass the inner membrane. Studies have 
shown that this transportation is the rate-limiting step
10
 along the acidic pathway and 
upregulation of StARD1 gene expression can markedly accelerate the bile synthesis through 
the acidic pathway
12
.  
Figure4. Enterohepatic circulation
13 
Bile acids synthesized in the liver are called primary bile acids. They are then conjugated to 
either glycine or taurine to form bile salts. Bile salts are actively secreted out of the 
hepatocytes by ATP-binding cassette sub-family B member 11 (ABCB11), together with 
phospholipids by ABCB4, and cholesterol by ATP-binding cassette sub-family G member 
5/8 (ABCG5/8)
14
. Bile salts function as an organic solvent and take phospholipids and 
cholesterol into the intestine via the bile ducts. In the intestine, part of the bile salts loose 
glycine and taurine and turn back into bile acids through bacteria digestion. These bile acids 
are defined as secondary bile acids and they are partially reabsorbed by the intestine and 
brought back to the liver via the portal vein. This circulation between liver and intestine is 
enterohepatic circulation (Fig 4). On the other hand, part of the cholesterol, secondary bile 
acids and bile salts are excreted into faces. 
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1.1.2 Cholesterol metabolism in the brain 
Brain is a cholesterol-rich organ, which accounts for 20-25% of total cholesterol in the whole 
body
15
. Except for the contribution in cell membranes, cholesterol is also the raw material for 
myelin. Myelin forms an electrically insulating layer surrounding the axons of some nerve 
cells, which is fundamental for the efficient transmission of neuronal signals. Cholesterol 
metabolism in the brain is separated from the rest of the body by the blood-brain barrier 
(BBB). BBB is a highly selective permeability barrier composed by the brain-specific 
endothelial cells. This barrier prevents the cholesterol, among many other hydrophobic 
substances, from fluxing in or out of the brain. Although the brain, similar to all the other 
peripheral tissues, expresses the specific receptors for lipoproteins and ABCA1, there is no 
evidence showing that there is cholesterol exchange through lipoproteins between the brain 
and the blood circulation. Instead, several studies have shown by isotope tracking that the rate 
of cholesterol biosynthesis in the brain equals to the rate of cholesterol turnover in both 
developmental and adult periods, which indicates that all or at least the majority of 
cholesterol supply in the brain relies on de novo biosynthesis
16
.  
The excretory pathways of cholesterol from the brain share the similarity with the bile acid 
synthesis in the liver (Fig 3). It is initiated by CYP7A, however continued by 24-hydroxylase 
(CYP46A1) instead of CYP27A1. The corresponding product 24(S)-hydroxycholesterol 
diffuses through BBB and circulates to the liver for further excretion
16
. Defects of cholesterol 
metabolism in the brain have been implicated in several neurodegenerative diseases, such as 
Smith-Lemli-Opitz syndrome and Niemann-Pick type C disease
17
. 
 
1.1.3 Plant sterols 
Plant sterols, as the name 
indicates, are found in the 
cell membranes of plants. 
The most common plant 
sterols in the human diet 
are campesterol and sitosterol
18
. Due to structure similarity (Fig 5), plant sterols are 
metabolized as cholesterol, but with far less efficiency in mammals. 2-5% of ingested plant 
sterols are absorbed at the small intestine, of which only 1 % reaches the blood circulation in 
the form of VLDL
19
. The consumption of plant sterols has increased during the past 10 years, 
mainly due to its potential benefit on cardiovascular health, because plant sterols has shown a 
strong effect on reducing plasma levels of cholesterol and LDL
20
. However, up-to-date, no 
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association between plasma levels of plant sterols and risk of cardiovascular diseases has 
been detected
21
. At the same time, the side effect of plant sterols in the brains and its potential 
role in promoting neurological diseases has become an increasing concern. Several studies 
confirmed that plant sterols can pass BBB and accumulate in the brains in a concentration-
dependent manner
22
 and the molecular mechanism is suggested to involve the HDL receptors 
expressed on the endothelial cells of BBB
23
. From meta-analysis plant sterols have been 
linked to amyotrophic lateral sclerosis, but in vitro role of plant sterols in the setting of the 
central nervous system is still under discussions
23
.  
 
  
 8 
1.2 INSULIN PHYSIOLOGY 
Glucose is the most direct energy source in the body. While many organs can also use fat and 
protein, the survival and normal function of the red blood cell and the brain is solely 
dependent on glucose supply. Insulin is a peptide hormone which plays an essential role in 
glucose clearance from the blood circulation by promoting its utilization primarily in the 
muscle, its short-term storage in the form of glycogen in the liver and its long-term storage in 
the form of fat in the adipose tissue.  
 
1.2.1 Insulin secretion in pancreatic β cells 
Insulin is secreted from β cells of the pancreatic islets in a glucose-dependent manner. 
Pancreatic islets, also known as islets of Langerhans, are the endocrine regions of pancreas. It 
consists of five major cell types: glucagon-producing α cells, insulin-producing β cells, 
somatostatin-producing δ cells, polypeptide-producing γ cells and ghrelin-producing Epsilon 
cells. After glucose stimulation, insulin secretion from the β cells follows a biphasic pattern. 
The first phase reaches its acute peak 4min after onset, and then drop back to a nadir around 
8-10 min. The second phase is characterized by a gradually increasing rate of insulin release, 
which reaches the plateau 25-30min after glucose stimulation
24
.  
Three key steps are involved in the process of insulin secretion: insulin sensing, the triggering 
pathway and the amplification pathway (Fig 6). The glucose-sensing mechanism involves the 
glucose entry and glycolysis. Glucose transporter 2 (GLUT2) is highly expressed on 
pancreatic β cells and facilitate glucose transportation with high capacity but low affinity, 
which maintains the glucose level in and out of the β cells constantly equal. Thereafter, 
glucose goes through glycolysis, a series of enzymatic reactions to break down glucose and 
produce ATP. Disturbance of either GLUT2 or the rate-limiting enzyme of glycolysis, 
glucokinase, impairs the glucose sensing capacity of the β cells25. Subsequently the elevated 
ATP/ADP ratio triggers the ATP-sensitive potassium channel (KATP channel), which leads to 
depolarization of cell membrane and calcium influx through voltage-dependent calcium 
channels. Elevated concentration of calcium, thereafter, stimulates the exocytosis of insulin. 
This is the triggering pathway, which explains the first-phase of insulin secretion
26
. The 
amplification pathway, which corresponds to the second phase of insulin release, is to a great 
deal KATP-independent, but the mechanism is not fully understood yet. Insulin granules in β 
cells can be divided into different pools based on their readiness for secretion: reserved pool, 
docked pool, readily-releasable pool and immediately-releasable pool. Some researchers 
favor the hypothesis that the triggering pathway is largely responsible for the secretion of the 
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immediately-releasable pool and the amplification pathway is signaling to promote the 
readiness of insulin granules; in another word, to convert the reserve, docked and readily-
releasable pools into its more ready status
27
.    
 
Figure6. Insulin granule pools and secretion pathway
27 
 
1.2.2 Insulin signaling for glucose utilization 
As is shown in Figure 7, insulin signaling starts from binding to its specific receptor, insulin 
receptor, on the cell membrane. Following the insulin binding, the insulin receptor goes 
through auto-phosphorylation; therefore activates its intrinsic kinase and recruits insulin 
receptor substrate (IRS). IRS-1/2 plays a critical role in mediating two major signaling 
pathways. While the Ras/ERK pathway is promoting cell growth, the PI3K/Akt pathway, also 
known as the protein kinase B (PKB) pathway, is taking charge of a series of metabolic 
processes: 1) Akt promotes protein synthesis through regulating mTOR signaling pathway. 2) 
Akt enhances glucose uptake by accelerating the recycling of glucose transport type 4 
(GLUT4). 3) In the muscle and the liver, Akt upregulates glycogenesis by mediating 
phosphorylation of glycogen synthase kinase (GSK3β). Glycogenesis is the biochemical 
process converting glucose into its short-term storage form, glycogen, after a series of 
enzymatic reactions during the well-fed state. In fasting state, glycogen in the liver breaks 
down into glucose and maintains the blood glucose level. During exercises, glycogen in the 
muscle supplies locally as the direct energy resource. 4) Fat is the long-term storage form of 
energy. In the liver and the adipose tissue, insulin signalling activates the transcription factor, 
Sterol regulatory element-binding protein 1 (SREBP-1), thus promotes fatty acid synthesis.  
 10 
 
Figure7. Insulin signaling 
1.2.3 Diabetes mellitus 
Diabetes mellitus is a group of metabolic diseases characterized by elevated level of blood 
glucose over a prolonged period. Diabetes is a fast-growing public health issue and estimated 
to have a prevalence of 366 million people worldwide in 2030
28
. There are three major types 
of diabetes: Type I (insulin dependent) diabetes, type II (noninsulin dependent) diabetes and 
gestational diabetes. In this thesis, we focus on introducing type II diabetes, whose 
prevalence is driven by obesity and takes up 90% of all the diabetic population. The 
pathogenesis of type II diabetes is not fully understood yet. At the epidemiological level, 
there is a strong correlation between onset of type 2 diabetes and lipid accumulation outside 
the adipose tissues, for example in the liver and the muscle
29
. Furthermore, the impairment or 
loss of first-phase insulin secretion is observed and confirmed by many investigators
24
. At 
molecular level, several lipid species have been proven to impair both insulin secretion and 
sensitivity. 
In pancreatic β cells, insulin secretion is dependent on elevated ATP/ADP ratio, which comes 
from glucose influx and glycolysis. In vitro studies on insulin-producing cell lines support the 
hypothesis that fatty acids affects insulin secretion by switching the balance between 
glycolysis and fatty acid oxidation inside the mitochondrial. For example, when islets are 
cultured in the glucose concentration which favors insulin secretion, the fatty acid oxidation 
is suppressed
30
. Reagents which inhibit the transportation of fatty acid into the mitochondrial 
for β oxidation boost insulin secretion from glucose-perfused islets31. Furthermore, capacity 
of insulin secretion is sensitive to cholesterol contents in the pancreatic β cells. The 
cholesterol homeostasis in the pancreatic β cells is finely balanced by de novo biosynthesis, 
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cholesterol efflux via HDL, and cholesterol uptake via LDL. Both up- and downregulation of 
the cholesterol content by manipulating these three pathways impair insulin secretion
32,33
. 
 
In the peripheral tissues, lipotoxicity interfere with insulin signaling at multiple levels. 
Ceramides, which is composed of sphingosines and a fatty acid, can inactivate Akt
34
 and 
therefore block insulin actions in the metabolic perspective. Diacylglycerol (DAG), which 
consists of two fatty acid chains and a glycerol molecule, can alter the pattern of IRS 
phosphorylation and therefore decrease insulin signaling
35
. Furthermore, low level of 
inflammation has been detected in obese population, and proinflammatory cytokines such as 
tumor necrosis factor (TNF) contributes to insulin resistance by inactivating IRS
36
.  
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1.3. PLATELET-DERIVED GROWTH FACTOR B (PDGFB) 
PDGFB has been known as a mitogen for many cell types of mesenchymal or neuro-
ectodermal origins. PDGFB is composed of a growth factor core domain which is necessary 
and sufficient for receptor binding and activation, and a retention motif at the C-terminal. The 
retention motif binds to heparin sulfate proteoglycan in the extracellular matrix, which 
defines the spatially distribution of PDGFB and affects its biological activity and action 
range. PDGFB forms homodimer (PDGF-BB), or heterodimer (PDGF-AB) by paring up with 
PDGFA. They initiate cell signalling by binding to platelet-derived growth factor receptors 
(PDGFRs). There are two forms of PDGFR, alpha and beta, and they also form homodimers 
Pdgfrα/α, Pdgfrβ/β and heterodimer Pdgfrα/β. In vitro studies have shown that PDGF-BB 
binds to Pdgfrα/α, Pdgfrβ/β and Pdgfrα/β while PDGF-AB binds to Pdgfrα/α and Pdgfrα/β. 
In vivo studies of PDGFB’s interaction with its receptors are clear yet. So far PDGF-BB has 
only been confirmed to act on Pdgfrβ/β37. 
 
1.3.1 Pericytes and PDGFB retention motif knockout mouse model 
PDGFB is mainly expressed by 
endothelial cells and it is well-known as 
a recruitment factor for pericytes in the 
field of vascular biology. As is shown in 
Figure 7, pericytes are contractile cells 
embedded in the basement membrane 
and outlining endothelial cells of 
capillaries and venules
38
. Proper coverage of pericytes along the blood vessels is very 
important for angiogenesis, vascular maturation and stability. Physiologically after being 
secreted from endothelial cells, PDGFB is highly concentrated at basement membranes 
because of its heparin sulfate proteoglycan binding domain (HSPG-BD). On the other hand, 
Pdgfrβ is expressed on pericytes. Through ligand-receptor attraction, pericytes are recruited 
to cover blood vessels.  
In order to study PDGFB signaling, a large number of mutations in PDGFB and PDGFR 
genes have been generated in mice. Unfortunately, knock-out mutants for Pdgfb, Pdgfrα or 
Pdgfrβ are lethal at embryonic state, which means that PDGFB signaling is crucial for 
embryonic development. In our study, we used the Pdgfb
ret/ret 
mice model, in which the 
HSPG-BD is knocked-out while the growth factor core domain is not affected. PDGFB in 
Pdgfb
ret/ret 
has slightly different signaling because of its local distribution. But since this gene 
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manipulation is much milder, these mice are viable. Pdgfb
ret/ret
 has been intensively studied in 
BBB. BBB is a specific physical barrier mainly composed of endothelial cells to maintain the 
Central Nervous System (CNS) enclosed. As shown in Figure 8, when the retention motif is 
missing, PDGFB is no longer highly concentrated on the basement membrane, thus pericytes 
are partially detached and the BBB becomes leaky
39
. In liver however, this mice model has 
been poorly studied. 
 
Figure 8. Mechanism of pericyte deficiency in Pdgfb
ret/ret
 
 
1.3.2 PDGFB signaling in the liver 
Under physiological conditions, hepatic PDGFB is produced from portal veins
40
. From 
vascular perspective, PDGFB signalling in the liver is special, because PDGFB is not 
predominantly expressed from the sinusoidal endothelial cells, and the recruitment of liver 
pericytes is independent of PDGFB
41
. Hepatic PDGFB is well-known as a potent mitogen for 
HSCs and critically involved in fibrogenesis following injuries of different etiologies. In 
biliary diseases, PDGFB is detected in newly-proliferated cholangiocytes
40
 and in non-biliary 
diseases, pathological PDGFB is suggested to be released from macrophages
42
. PDGFRα and 
PDGFRβ are expressed on HSCs. After binding to PDGFB, PDGFRs undergoes auto-
phosphorylation and recruits its adaptor Grb2. Activation of PDGFRs transduces signals 
through a wide spectrum of pathways including COX2-PGs-cAMP, PI3K/PKB, Ras/ERK 
and ion channels. All these pathways serve to help HSCs survive or proliferate
43-45
. 
Proliferation of HSCs is the first step for HSC activation, which is followed by migration, 
trans-differentiation into a myofibroblastic cell type and production of extracellular matrix. In 
vitro, PDGFB promotes the proliferation, but not trans-differentiation, which indicates that 
the whole process of HSC activation also requires other stimuli such as reactive oxygen 
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species (ROS) and inflammatory cytokines
42
. However, overexpression of PDGFB in 
hepatocytes in vivo gives rise to liver fibrosis
44
. 
 
Figure 9. Mitogenic pathways of PDGF in hepatic stellate cells (HSCs)
43
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2. AIM OF THIS THESIS 
PDGFB has been previously known as a major recruitment factor for pericytes, and therefore 
plays an important role in angiogenesis and normal vascular function. In our study, we used 
Pdgfb
ret/ret
 to study the postnatal effect of PDGFB signaling in cholesterol and glucose 
metabolism.  
In the brains, pericyte deficiency is confirmed in Pdgfb
ret/ret
 and this leads to BBB leakage. 
BBB has been shown as an important barrier to keep the integrity of brain cholesterol 
metabolism. In Paper I and II, we used Pdgfb
ret/ret
 as a BBB leakage model and observed 
how the cholesterol metabolism in the brain has changed. 
In the liver, PDGFB is critically involved in fibrogenesis following liver injuries, but the 
physiological function of PDGFB is poorly investigated. In Paper III, we started from 
localizing PDGFB and PDGFRβ expression in the liver. Meanwhile, based on the 
observations in Pdgfb
ret/ret
, we aimed to analyze the metabolic consequences of disrupted 
PDGFB signaling in the liver 
Paper IV aimed to explore the role of PDGFB signaling in the pancreatic islets and try to 
decipher why Pdgfb
ret/ret
 has faster glucose clearance and how PDGFB participates to regulate 
glucose metabolism. 
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3 PAPERS AND MAIN RESULTS 
Since the material and method, the results and the discussions are presented in details in each 
paper/manuscript, only a short summary of the main findings are highlighted below. 
 
3.1 PAPER I&II; ROLE OF BBB INTEGRITY IN BRAIN CHOLESTEROL 
METABOLISM 
In the brain, PDGFB is the critical molecule for the recruitment of pericytes. In Pdgfb
ret/ret
, 
pericyte coverage is reduced by 70% on the BBB, and this leads to increased permeability of 
a range of low- and high-molecular mass tracers. In our study, we used Pdgfb
ret/ret
 as a model 
of defective BBB and studied the biological importance of BBB to cholesterol metabolism in 
the brain. As is summarized in Figure 10, when BBB is intact, cholesterol supply in the brain 
comes from de novo biosynthesis. Although endothelial cells of BBB express receptors for 
both HDL and ApoB-containing lipoproteins, cholesterol in the circulation cannot pass BBB 
through transcytosis (A). Pericytes have been shown to inhibit transcytosis across the BBB, 
and when pericytes are deficient in Pdgfb
ret/ret
, cholesterol together with its analog plant 
sterols fluxes into the brain at a concentration-dependent manner (B). On the other side, 
replaced cholesterol from metabolic turnover is excreted out the brain in the form of 24-
hydroxycholesterol (24-OHC). 24-OHC is an oxidized metabolite of cholesterol, and 
important for sending negative feedback to the de novo biosynthesis in the brain. Under 
physiological conditions, 24-OHC can pass BBB into the circulation through both passive 
and active transportation (A). In Pdgfb
ret/ret
, a significantly stronger efflux of 24-OHC is 
speculated, as indicated by the reduced level of 24-OHC in the brain and less concentration 
difference in and out of the brain. Because the negative feedback from 24-OHC is reduced, 
the de novo biosynthesis of cholesterol in the brain is increased. On the contrary, plant sterols 
cannot be excreted by the same pathway, and therefore in Pdgfb
ret/ret
, more plant sterols are 
accumulated in the brain. 
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Figure 10. Theoretical models for metabolic consequences of brain cholesterol from defective BBB 
3.2 PAPER III; ROLE OF PDGFB IN THE LIVER PATHOPHYSIOLOGICAL 
CHOLESTEROL REGULATION 
PDGFB in the liver is an essential molecule for initiating fibrogenesis by activating HSCs 
following pathological stimuli. Under physiological senario, however, the role of hepatic 
PDGFB signaling is poorly investigated.  
In Paper III, we started from visualizing the expression of PDGFB and its receptor PDGFRβ 
in the liver. In agreement with the previous study, we confirmed that PDGFB is expressed 
from the endothelial cells of portal veins. In addition, PDGFB is also expressed in the 
cholangiocytes of bile ducts in the portal area. This finding guided us to characterize in 
details the portal mesenchymal cells which express PDGFRβ. Using a panel of markers, we 
found that mesenchymal cells surrounding the portal endothelial cells are expressing ASMA 
but not PDGFRα, while mesenchymal cells surrounding the bile ducts are expressing 
PDGFRα but not ASMA. Both periductal and perivascular mesenchymal cells express 
desmin and colocalize with collagen deposit.  
By using PDGFB knockouts and PDGFRβ overreactive mouse model, we detected a direct 
link between elevated PDGFB signaling and monocyte infiltration both generally in the liver 
and intensively clustered around the bile ducts. The clustering of monocytes around the bile 
ducts is defined as portal inflammatory infiltrate(PII) and is of great clinical interest due to its 
ubiqutous presence in biliary and non-biliary liver diseases. To further explore the postnatal 
effect of PDGFB, we used Pdgfb
ret/ret
, where the hepatic PDGFB signaling is slightly 
elevated. In accordance to our expectation, general monocyte infiltration and PII also take the 
place in Pdgfb
ret/ret
, and in parallel we found two other defects related to the bile ducts: bile 
duct dilation and deficiency of periductal mesenchymal cells.  
Bile duct is the fundamental structure for bile excretion. Pdgfb
ret/ret
 shows intolerance to high 
cholesterol diet and develops hepatic steatosis. However the lipid retention in the liver is not 
due to defects in bile duct function, but suppression of VLDL secretion. Later we proved that 
the VLDL suppression is mediated by PDGFB-induced inflammation represented by PII. 
When we high-jacked the inflammation by depleting neutrophils from the circulation, hepatic 
steatosis, together with PII and VLDL suppression, is normalized. 
At last, this project finishes with a detailed profiling of the immune populations in the liver. 
We showed that CD8+ T cells, together with Interferon gamma, are significantly upregulated 
while NKT cells are decreased in Pdgfb
ret/ret
. 
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3.3 PAPER IV; ROLE OF PLATELET-DERIVED GROWTH FACTOR B IN 
INSULIN SECRETION 
It has been previously reported that Pdgfb
ret/ret
 has faster glucose clearance due to increased 
insulin sensitivity in the liver
46
. At the beginning of Paper IV, we performed intraperitoneal 
glucose tolerance test on mice of different ages and at different time points during the day. 
Our results confirm that Pdgfb
ret/ret
 clears glucose in a more efficient way, and this phenotype 
is not affected by age or the diurnal cycle. The previous study assumed that Pdgfb
ret/ret
 has 
less efficiency of PDGFB signaling in the liver, in a similar way as confirmed on the BBB. It 
reported that the sinusoids in Pdgfb
ret/ret
 are more permeable to fluorescent tracers, and the 
liver uptakes more glucose when challenged with high dose of insulin
46
. From Paper III, 
however, we showed that hepatic PDGFB signaling is slightly higher in the liver. We then 
performed intraperitoneal insulin tolerance test together with glucose uptake assay. Our 
results showed that Pdgfb
ret/ret
 has similar level of insulin sensitivity in the peripheral tissues 
and the liver is not taking up more glucose compared with the control littermates. We 
explained the faster glucose clearance in Pdgfb
ret/ret
 as a more efficient patter of insulin 
secretion. Although Pdgfb
ret/ret
 showed less insulin contents in the pancreas and inclined to 
secrete less insulin during the whole process of intraperitoneal glucose tolerance test. 
However, the first phase of insulin secretion in Pdgfb
ret/ret
 is significantly earlier and stronger 
compared to the control littermates.  
To explore the mechanism how PDGFB signaling regulates insulin secretion, we first 
checked vasculature in pancreatic islets, which includes vessel density, pericyte coverage, 
perfusion and permeability. All of these parameters show no difference in Pdgfb
ret/ret
, which 
indicates that PDGFB is not a critical molecule for pericyte maintenance in pancreatic islets 
and the difference in insulin secretion cannot be justified by vascular changes. Furthermore 
we examined the islet size, proliferation rate and ex vivo capacity of insulin secretion after 
glucose stimulation. All the results show no difference in Pdgfb
ret/ret
, which suggests that it is 
a systematic effect, which leads to the earlier and stronger insulin secretion at its first phase. 
More investigations are needed to set up the link between the changes of PDGFB signaling in 
Pdgfb
ret/ret
 and the insulin secretion pattern we observed.  
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